Hua Zhong

CAMPASS: benmelstobart + anlotinib verlengt PFS versus pembrolizumab in PD-L1+ NSCLC

Andamertinib bij gevorderde NSCLC met EGFR-exon 20-inserties na platina of immunotherapie

Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blin...